{"altmetric_id":4684717,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Novartis ( Novartis Pharmaceuticals )"],"first_seen_on":"2015-10-28T11:34:43+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1503514808,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01524783","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01524783?term=RADIANT-4&rank=1"],"nct_id":"NCT01524783","pubdate":"2011-12-22T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4)","type":"clinical_trial_study_record"},"altmetric_score":{"score":18,"score_history":{"1y":7,"6m":7,"3m":7,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":18},"context_for_score":{"all":{"total_number_of_other_articles":8418826,"mean":7.0849522326371,"rank":490065,"this_scored_higher_than_pct":94,"this_scored_higher_than":7923679,"rank_type":"exact","sample_size":8418826,"percentile":94},"similar_age_3m":{"total_number_of_other_articles":245842,"mean":9.7953128729543,"rank":21311,"this_scored_higher_than_pct":91,"this_scored_higher_than":224412,"rank_type":"exact","sample_size":245842,"percentile":91},"this_journal":{"total_number_of_other_articles":24831,"mean":10.521629963753,"rank":1606,"this_scored_higher_than_pct":93,"this_scored_higher_than":23196,"rank_type":"exact","sample_size":24831,"percentile":93},"similar_age_this_journal_3m":{"total_number_of_other_articles":1132,"mean":14.802647214854,"rank":103,"this_scored_higher_than_pct":90,"this_scored_higher_than":1028,"rank_type":"exact","sample_size":1132,"percentile":90}}},"demographics":[],"counts":{"total":{"posts_count":3},"news":{"unique_users_count":3,"unique_users":["medpage_today","my_news_desk","oncology_nurse_advisor"],"posts_count":3}},"posts":{"news":[{"title":"Promising Tx in GI Neuroendocrine Tumors","url":"http:\/\/ct.moreover.com\/?a=22824678089&p=1pl&v=1&x=krgRdgE9Vb938l4ps40Llw","license":"public","citation_ids":[4684714,4684717],"posted_on":"2015-09-27T19:01:29+00:00","summary":"Action Points Note that these studies were published as abstracts and presented at a conference.","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}},{"title":"Afinitor f\u00e5r ut\u00f6kat EU-godk\u00e4nnande f\u00f6r behandling av spridda neuroendokrina tum\u00f6rer, NET","url":"http:\/\/ct.moreover.com\/?a=26906351289&p=1pl&v=1&x=OfnThILH6NBbplriSOHP9w","license":"public","citation_ids":[4684717],"posted_on":"2016-06-15T07:35:00+00:00","summary":"Everolimus som sedan tidigare godk\u00e4nts f\u00f6r spridd NET med ursprung i bukspottk\u00f6rteln \u00e4r nu \u00e4ven godk\u00e4nd f\u00f6r behandling av vissa typer av spridda neuroendokrina tum\u00f6rer med ursprung fr\u00e5n magtarmkanalen eller lungan 1.","author":{"name":"My News Desk","url":"http:\/\/www.mynewsdesk.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/847\/normal\/Screen_Shot_2016-01-27_at_11.32.34.png?1453894453"}},{"title":"Everolimus Maintains Quality of Life in Neuroendocrine Tumors","url":"http:\/\/ct.moreover.com\/?a=31610435310&p=1pl&v=1&x=Xx2ZQGnvaMekT8TQcdZ_GQ","license":"public","citation_ids":[4684717],"posted_on":"2017-08-23T19:00:08+00:00","summary":"August 23, 2017 A previous analysis demonstrated that everolimus prolonged progression-free survival \u2014 the primary endpoint of the study \u2014 compared with placebo.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}}]}}